Torii

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024
Torii, Research, Calendar, Chemistry, Marketing, FDA, Table, Sale, Travel, GAAP, Collaboration, Patient, Clinical trial, Net, Bank statement, Insurance, Pharmaceutical industry

WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Verrica recognized product revenue of $1.9 million in the fourth quarter of 2023.
  • Verrica reported a net loss of $24.6 million for the fourth quarter of 2023, compared to a $5.9 million net loss for the same period in 2022.
  • Selling, general and administrative expenses were $17.0 million in the fourth quarter of 2023, compared to $3.2 million for the same period in 2022.
  • Research and development expenses were $5.3 million in the fourth quarter of 2023, compared to $3.0 million for the same period in 2022.

Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan

Retrieved on: 
Friday, December 15, 2023
Molluscum contagiosum, FDA, Marketing, Patient, Safety, Dermatology, Therapy, Skin, Torii, Pharmaceutical industry

The Phase 3 trial was conducted in Japan and is a double blind, randomized and parallel-group comparison study to evaluate the efficacy and safety of TO-208 in comparison to placebo, when applied once every 21 days for up to four applications in patients with molluscum.

Key Points: 
  • The Phase 3 trial was conducted in Japan and is a double blind, randomized and parallel-group comparison study to evaluate the efficacy and safety of TO-208 in comparison to placebo, when applied once every 21 days for up to four applications in patients with molluscum.
  • The top-line results show that the proportion of subjects achieving complete clearance of all treatable molluscum lesions at the completion of the confirmatory study, the primary endpoint of efficacy, was statistically significant versus placebo.
  • “We are obviously excited by the positive results from this confirmatory Phase 3 trial for TO-208 for the treatment of molluscum in Japan, which underscores the consistent safety and efficacy of VP-102 and FDA-approved YCANTH,” said Ted White, Chief Executive Officer of Verrica Pharmaceuticals.
  • Torii intends to submit a manufacturing and marketing application for the product in Japan, based on the results of the Phase 3 trial and other studies currently being conducted.

Torii Ushers in a New Era of SaaS Management with Enhanced, Generative AI-powered Platform

Retrieved on: 
Wednesday, September 13, 2023
Apps, Applications, Technology, Security, Other Technology, Professional Services, Software, Networks, Data Analytics, Data Management, Artificial Intelligence, United States Secretary of Labor, Software as a service, Gartner, API, SMP, SMPS, Organization, Documentation, Entrepreneurship, AI, Medical device, Sales, Slack, Torii

The only SMP powered by generative AI, Torii’s enhanced platform equips bandwidth-strapped IT teams to automate time-consuming tasks, cut SaaS spend, and power quicker, actionable insights.

Key Points: 
  • The only SMP powered by generative AI, Torii’s enhanced platform equips bandwidth-strapped IT teams to automate time-consuming tasks, cut SaaS spend, and power quicker, actionable insights.
  • Powered by generative AI and with a newly open platform, Torii is not only solving these challenges with the latest platform release, but is redefining SaaS management and setting new standards for the industry.
  • Some of the first-to-market generative AI-powered capabilities include:
    AI Contract Ingestion: Users can instantly upload contracts to Torii with AI Contract Ingestion.
  • To learn more about how the Torii platform can simplify your SaaS ecosystem, visit our website .

Archway Protocol, the Value Capture Chain, is Now Live

Retrieved on: 
Monday, July 3, 2023
Ethereum, Blockchain, Phi Lab, Protocol, Dame Alice Owen's School, Decentralized finance, Griffin, Terra, Ecosystem, Torii, Refinancing, Environment, Cryptocurrency, Cosmos, Vectis, Archway

George Town, Cayman Islands, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- The Archway Foundation announces today that the Archway Protocol has officially launched, with the production of its first block. Archway is a Cosmos-native Layer 1 incentivized blockchain designed to enable developers to capture the value they create for a network. This has never been more important as the global blockchain space stands on the precipice of technological commoditization.

Key Points: 
  • George Town, Cayman Islands, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- The Archway Foundation announces today that the Archway Protocol has officially launched, with the production of its first block.
  • Archway is a Cosmos-native Layer 1 incentivized blockchain designed to enable developers to capture the value they create for a network.
  • Archway aims to provide developers with a more equitable distribution of value and opportunities to build self-sustainable dapps, while simultaneously benefiting from the value they bring to the network.
  • The Torii Testnet launched in April of that same year, enabling the Archway community to test the protocol's core modules.

Automation Cynicism Signals Challenges for AI, New Torii Report Finds

Retrieved on: 
Thursday, June 22, 2023
Software, Networks, Artificial Intelligence, Data Management, Technology, Apps, Applications, Other Technology, Security, Software as a service, Education, Gartner, Learning curve, ChatGPT, Automation, Pulse, Organization, Distribution, AI, Online shopping, Sales, Cassette tape, Torii

Torii , creator of the Distributed SaaS Management Platform for IT professionals, today announced its newest report, “ State of IT Automation: Breakthrough or Buzzkill?

Key Points: 
  • Torii , creator of the Distributed SaaS Management Platform for IT professionals, today announced its newest report, “ State of IT Automation: Breakthrough or Buzzkill?
  • To do this, IT teams are increasingly turning to AI and automation solutions.
  • Barriers to automation remain high: 64% of IT professionals cite a lack of tool education, and nearly half (44%) cite poorly designed automation tools.
  • Click here to access Torii’s report, “ State of IT Automation: Breakthrough or Buzzkill ?”
    Looking for more insights into IT professionals’ views, tech adoption, challenges, and perceptions of SaaS?

Torii Earns Top Rating for SaaS Management in G2 Summer 2023 Grid Reports

Retrieved on: 
Thursday, June 15, 2023
Data Management, Security, Apps, Applications, Technology, Other Technology, Software, Networks, Spend, Software as a service, G2, SMP, Negotiation, Blog, SMPS, Distribution, Risk, Grid, Mobile phone, Torii

Torii , creator of the Distributed SaaS Management Platform (SMP) for IT professionals, today announced it is the #1 rated SMP vendor in four G2 Summer 2023 SaaS Management Grid Reports.

Key Points: 
  • Torii , creator of the Distributed SaaS Management Platform (SMP) for IT professionals, today announced it is the #1 rated SMP vendor in four G2 Summer 2023 SaaS Management Grid Reports.
  • For the 5th consecutive quarter, Torii received top customer satisfaction scores in the categories of SaaS Operations and SaaS Spend Management for both Midmarket and Overall Enterprises.
  • They've effectively eliminated the risk of unnoticed renewals, preventing unnecessary costs.”
    To access the G2 SaaS Operations and Spend Management Summer 2023 Grid reports, click here .
  • To learn how to use Torii to automate key SaaS management processes, check out this upcoming webinar, “Automation is More than Just Onboarding and Offboarding ,” on June 28, 2023.

New Torii Report Finds 73% of CIOs Lack Insights into their Cloud App Spend

Retrieved on: 
Thursday, April 27, 2023
Data Management, Security, Apps, Applications, Technology, Other Technology, Software, Spend, Pressure, Software as a service, Education, Face, Fear, Job satisfaction, Organization, Distribution, Investment, CIO, Shadow IT, Computer security, Risk management, Torii

However, they need to be empowered to address major challenges,” said Uri Haramati, CEO of Torii.

Key Points: 
  • However, they need to be empowered to address major challenges,” said Uri Haramati, CEO of Torii.
  • Seventy five percent of CIOs say their inability to identify wasted SaaS spend is a threat to their company’s success.
  • CIOs feel blind to SaaS spend management: Despite CIOs’ concerns, 73% say their organization does not have a strategic framework for evaluating app rationalization and license usage.
  • For additional survey findings and implications, access Torii’s complimentary “State of IT Mind” report, here .

IT Pros Rate Torii Tops for SaaS Management in G2 Spring 2023 Grid Reports

Retrieved on: 
Tuesday, April 11, 2023
Data Management, Other Technology, Apps, Applications, Technology, Software, Spend, Software as a service, SMP, Blog, Privacy, SMPS, Distribution, Risk, Ecosystem, Grid, Mobile phone, Retail, G2, Torii

Torii , creator of the Distributed SaaS Management Platform (SMP), today announced it is the highest-rated SMP vendor in two new G2 Spring 2023 SaaS Management Grid Reports.

Key Points: 
  • Torii , creator of the Distributed SaaS Management Platform (SMP), today announced it is the highest-rated SMP vendor in two new G2 Spring 2023 SaaS Management Grid Reports.
  • Once again, Torii received top customer satisfaction scores for both SaaS Operations and SaaS Spend Management.
  • But with SaaS usage and ownership spread throughout companies, it’s impossible for often-overwhelmed IT teams to get a handle on their usage and spend,” said Uri Haramti, CEO of Torii.
  • For more information on what these G2 Reports indicate for businesses, read this blog .

Torii Wins Awards for Best Customer Support and Great Place to Work

Retrieved on: 
Tuesday, March 28, 2023
Professional Services, Data Management, Apps, Applications, Technology, Human Resources, Software, DNA, Software as a service, Culture, Policy, SMP, Meta-analysis, Marketing, Organization, Distribution, Customer service, Research, Shadow IT, Hand, Management, Sales, G2, Gallup, Torii

It was also recognized by the Stevie Sales & Customer Service Awards for its outstanding customer success team.

Key Points: 
  • It was also recognized by the Stevie Sales & Customer Service Awards for its outstanding customer success team.
  • These awards exemplify why so many businesses rely on Torii for discovering, managing, and reducing the costs of their cloud applications.
  • Torii’s Customer Success team also works closely with Sales, Marketing, and Product departments to ensure company-wide commitment to customer experience.
  • This holistic approach is why Torii was named a Customer Service Department of the Year by the Stevie Sales & Customer Service Awards, which recognizes organizations that go above and beyond for customer success.

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023
Skin, New Drug Application, Dermatology, Therapy, CMC, Insurance, Cantharidin, Molluscum contagiosum, Table, Bank statement, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Part, GAAP, Patient, Pharmacokinetics, Food, Carcinoma, Collaboration, FDA, Research, Safety, WEST, PDUFA, Wart, Pharmaceutical industry, Vaccine, Cryptocurrency, Torii

WEST CHESTER, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Verrica expects to initiate Part 2 of its ongoing Phase 2 study in basal cell carcinoma in the second quarter of 2023.
  • Verrica reported a net loss of $5.9 million for the fourth quarter of 2022, compared to a $9.5 million loss for the same period in 2021.
  • Research and development expenses were $3.0 million in the fourth quarter of 2022, compared to $3.4 million for the same period in 2021.
  • General and administrative expenses were $3.2 million in the fourth quarter of 2022, compared to $5.1 million for the same period in 2021.